Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Re��onja Robert) .

71 - 80 / 211
Na začetekNa prejšnjo stran45678910111213Na naslednjo stranNa konec
71.
Priporočila za zobozdravstveno obravnavo odraslih bolnikov z rakom glave in vratu v Sloveniji, zdravljenih z obsevanjem
Aleš Fidler, Aleksandar Aničin, Vojislav Didanovič, Tadej Dovšak, Boris Gašpirc, Aleš Grošelj, Andrej Kansky, Matic Koren, Jana Krapež, Hojka Kuralt, Marko Kuralt, Boštjan Lanišnik, Romana Mance Kristan, Jošt Pavčič, Luka Prodnik, Peter Pukl, Tadej Ostrc, Milan Kuhar, Eva Skalerič, Robert Šifrer, Valerija Skopec, Primož Strojan, 2022, izvirni znanstveni članek

Povzetek: Priporočila za zobozdravstveno obravnavo bolnikov z rakom glave in vratu (RGV) v Sloveniji, zdravljenih z obsevanjem sledijo priporočilom The Royal College of Surgeons of England v sodelovanju z The British Society for Disability and Oral Health, dopolnjujejo Priporočila za obravnavo bolnikov z rakom glave in vratu v Sloveniji in hkrati upoštevajo obstoječe zmožnosti slovenskega zdravstvenega sistema. Namen priporočil je prepre-čevanje oz. zmanjšanje zapletov v ustni votlini, ki nastanejo zaradi obsevanja. Opredeljujejo način zobozdravstvene oskrbe pred, med in po zdravljenju raka na vseh treh nivojih zobozdra-vstvene oskrbe, kar zagotavlja njeno pravočasnost in dostopnost. Priporočila predstavljajo poenoteno mnenje vseh deležnikov na področju zobozdravstvene obravnave bolnikov z RGV v državi.
Ključne besede: onkologija, zobozdravstvena obravnava, obsevanje, ustna votlina, priporočila
Objavljeno v DiRROS: 14.07.2022; Ogledov: 579; Prenosov: 203
.pdf Celotno besedilo (1,45 MB)

72.
In memoriam: izr. prof. dr. Sonja Horvat Marolt – v spomin (1930 – 2022)
Robert Brus, 2022, drugi sestavni deli

Objavljeno v DiRROS: 12.07.2022; Ogledov: 608; Prenosov: 180
.pdf Celotno besedilo (89,69 KB)

73.
Good survival of broadleaf tree species in a four-year-old plantation in the Slovenian Karst
Nina Škrk, Kristjan Jarni, Robert Brus, 2022, izvirni znanstveni članek

Povzetek: Six broadleaf tree species (Celtis australis L. – Mediterranean hackberry, Quercus petraea (Matt.) Liebl. – sessile oak, Fagus sylvatica L. – European beech, Prunus avium L. – wild cherry, Juglans regia L. – Persian walnut and Acer pseudoplatanus L. – sycamore maple) were planted in 2012 in a trial in the Slovenian Karst on two sites differing in productivity to test their suitability for use in the conversion of old pine stands into ecologically more stable broadleaf forests and to investigate their possible response to the harsher growth conditions predicted in the future. The selected economically interesting tree species have higher timber quality than broadleaves which regenerate naturally (e.g., Ostrya carpinifolia, Fraxinus ornus, Quercus cerris). Measurements were taken in 2017, after four growth seasons. All planted species except Fagus sylvatica had a high survival rate. In total, 70% of all seedlings survived, which shows promising potential. The survival rate was higher at the site on flat terrain than at the site on a slope. Prunus avium was the most successful of all planted species in terms of survival rate, at 83%, and other measured parameters (height, height increment, stem diameter, vitality and quality), and Fagus sylvatica was the least successful, with a survival rate of only 20%. Celtis australis had the highest survival rate, at 87%. Acer pseudoplatanus had the largest differences in measured parameters between the more and less productive sites among all planted species. Quercus petraea showed high resistance to xeric conditions and is expected to be the most successful in conversions. All planted species except Fagus sylvatica show favourable initial potential for the future conversion of Karst pine forests.
Ključne besede: forest conversion, broadleaves, survival rate, seedlings quality, climate change
Objavljeno v DiRROS: 28.06.2022; Ogledov: 2149; Prenosov: 970
.pdf Datoteka (3,13 MB)

74.
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Tanja Čufer, Katja Mohorčič, Maximilian J Hochmair, 2022, izvirni znanstveni članek

Povzetek: Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
Ključne besede: non-small cell lung carcinoma -- drug therapy -- genetics, molecular targeted therapy, real-world data, capmatinib, targeted therapy
Objavljeno v DiRROS: 24.06.2022; Ogledov: 724; Prenosov: 551
.pdf Celotno besedilo (943,38 KB)
Gradivo ima več datotek! Več...

75.
76.
77.
Non-native forest tree species in Europe : ǂthe ǂquestion of seed origin in afforestation
Paraskevi Alizoti, Jean-Charles Bastien, Debojyoti Chakraborty, Marcin Miroslav Klisz, Johan Kroon, Charalambos Neophytou, Silvio Schueler, Marcela van Loo, Marjana Westergren, Monika Konnert, Robert Brus, 2022, izvirni znanstveni članek

Povzetek: Non-native forest tree species have been introduced in Europe since the 16th century, but only in the second half of the 20th century the significance of the seed source origin for their economic use was recognized, resulting in the establishment of numerous provenance trials at a national, regional, European and International level, as those led by IUFRO. Breeding programs have also been launched in the continent for the most economically important species. Aim of this work is the formulation of provenance recommendations for planting of five non-native tree species in Europe (Douglas fir, grand fir, Sitka spruce, lodgepole pine and black locust), based on the information obtained from twenty countries, in the frame of the EU FP-1403 NNEXT Cost Action. The survey revealed that official and non-official national recommendations, based on provenance research results, have been elaborated and followed at a different level and extend for the above five species, but only for Douglas fir recommendations exist in almost all the participating to the survey countries. The compilation of provenance recommendations across Europe for each species is presented in the current work. Besides the recommended introduced seed sources, European seed sources are also preferred for planting, due to ease of access and high availability of forest reproductive material. European breeding programs yielding genetic material of high productivity and quality constitute currently the seed source of choice for several species and countries. Consolidation of trial data obtained across countries will allow the joint analysis that is urgently needed to draw solid conclusions, and will facilitate the development of ‘Universal-Response-Functions’ for the species of interest, rendering possible the identification of the genetic material suitable for global change. New provenance trial series that will test seed sources from the entire climatic range of the species, established in sites falling within and outside the environmental envelopes of their natural ranges, are urgently needed to pinpoint and understand the species-specific climate constraints, as well as to correlate functional traits to the seed origin and the environmental conditions of the test sites, so that the selection of suitable forest reproductive material of non-native tree species in the face of climate change can be feasible.
Ključne besede: provenance recommendations, provenance testing, breeding programs, adaptation, exotic tree species, Douglas fir, Sitka spruce, grand fir, lodgepole pine, black locust
Objavljeno v DiRROS: 09.02.2022; Ogledov: 811; Prenosov: 640
URL Povezava na celotno besedilo
Gradivo ima več datotek! Več...

78.
Latent preferences of residents regarding an urban forest recreation setting in Ljubljana, Slovenia
Anže Japelj, Robert Mavsar, Donald G. Hodges, Marko Kovač, Luka Juvančič, 2016, izvirni znanstveni članek

Povzetek: The goal of this study is to assess residents' preferences for a set of attributes describing the recreation setting in an urban forest (outstanding trees, forest openings, waymarks and information boards, and paved walking trails) and to explore the heterogeneity of those preferences. It was captured by a four-class latent class model used to segment a sample of residents of Ljubljana (the capital of Slovenia), who responded to a choice experiment-based poll. The survey focused on the Rožnik urban forest, for which preferences (also willingness-to-pay) for hypothetical changes in the attributes were assessed. Respondents in class 1 were invariant to changes in the recreation setting. Those in class 2 and 4 stated positive preferences for having more outstanding trees. Class 3 and 4 were in favour of increasing the area of forest openings and enhancing the maintenance of waymarks and information boards. Those in class 4 expressed positive preferences for more walking trails, whereas class 3 valued this negatively. Class membership was affected by respondent age, number of adults in the household, frequency of forest visits, income, and purpose of the visit.
Objavljeno v DiRROS: 12.01.2022; Ogledov: 817; Prenosov: 671
.pdf Celotno besedilo (480,00 KB)
Gradivo ima več datotek! Več...

79.
80.
Mnenje za spremljanje bolnikov po preboleli covidni pljučnici
Matjaž Turel, Natalija Edelbaher, Matjaž Fležar, Matevž Harlander, Peter Kecelj, Izidor Kern, Majda Kočar, Peter Kopač, Mitja Košnik, Robert Marčun, Igor Požek, Mirjana Rajer, Irena Šarc, Jurij Šorli, Dušanka Vidovič, Katarina Osolnik, 2021, izvirni znanstveni članek

Povzetek: Pljučnica je najpogostejši vzrok za težji potek okužbe z virusom SARS-CoV-2 in s hospitalizacijo. Potek covidne pljučnice je lahko različen; infiltrati, vidni na rentgenski sliki, se lahko resorbirajo spontano, včasih pa je potrebno zdravljenje s sistem-skimi glukokortikoidi. Ob odpustu iz bolnišnice zdravljenje običajno še ni končano, zato je Združenje pulmologov Slovenije v želji po enotnem obravnavanju bolnikov s covidno pljučnico izdelalo mnenje za obravnavo in sledenje bolnikov po od-pustu iz bolnišnice. Zavedamo se, da ob novi bolezni ne gre za dokončno priporočilo, saj bodo nova spoznanja o covidni pljučnici zanesljivo zahtevala obnavljanje priporočil.
Ključne besede: covid-19, mnenja, pljučnica, pulmologija, sistemski glukokortikoidi, covidna pljučnica
Objavljeno v DiRROS: 15.12.2021; Ogledov: 1087; Prenosov: 199
URL Povezava na datoteko

Iskanje izvedeno v 0.25 sek.
Na vrh